所有图片（1/1）
大包装询价 产品介绍 引用文献(0) 评论(0)
产品规格
物种
Human分子别名
MUC-1, EMA, MCD, PEMAccession
P15941-1表达序列
Leu1036-Gly1155, with C-terminal 8*His LSTGVSFFFLSFHISNLQFNSSLEDPSTDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGGGGSHHHHHHHH表达宿主
HEK293分子量
11-15&8kDa纯度
>95% by SDS-PAGE内毒素含量
<0.1EU/μg标记
Unconjugated标签
His Tag性状
Lyophilized powder缓冲体系
PBS, pH7.4溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1、Qing L. et al. (2022) MUC1: An emerging target in cancer treatment and diagnosis. Bull Cancer. 109(11): 1202-1216.
背景介绍
- MUC1 is a highly glycosylated transmembrane mucin on the luminal surface of epithelial cells, protecting them from extreme factors. In cancer cells, MUC1 expression is upregulated and the protein structure, glycosylation level and spatial distribution are altered. It was found that upregulated MUC1 is involved in the regulation of several signaling pathways and plays an instrumental role in tumor cell metabolism, apoptosis, epithelial mesenchymal transition and distant metastasis. MUC1 glycosylation insufficiency leads to exposure of novel antigenic epitopes that can be used as specific targets for therapy and diagnosis. In addition, MUC1 was found to be closely related to HIF and can form a positive feedback loop leading to hypoxic malignant tumor progression. Currently, MUC1-based targeted drugs include monoclonal antibodies, antibody-coupled drugs, aptamers and cancer vaccines, some of which have already entered clinical trials.
电泳(SDS-PAGE)
![item.picture[0].fileOrgName](https://univ-njua.oss-cn-shanghai.aliyuncs.com/prod/202303/d5c91e8eb8ba454daaed0ca55d86dd0e.png)
2μg (R: reducing conditions, N: non-reducing conditions).
引用文献(0)
评论(0)